About MobiDrop

MobiDrop provides the infrastructure for producing high-quality biological data for AI for Science. We transform real biological systems into accurate, comprehensive, rapidly generated, and cost-effective AI-ready data—and help AI make sense of it.

Company Profile

Founded in 2018, MobiDrop Biotech provides infrastructure for producing high-quality biological data for AI for Science.

Focused on transforming real biological systems into high-quality, AI-ready data, MobiDrop has built a full-stack technology portfolio spanning single-cell instruments, microfluidic chips, biochemical reagents, bioinformatics, and automated experimentation. By enriching biological samples and measuring them more comprehensively, accurately, and cost-effectively, we produce life-science data at scale that AI models can learn from, validate, and apply—advancing biological foundation models and virtual cells.

Jiaxing, China: Global HQ (R&D & Manufacturing Center)

Shanghai, China: Innovation & Business Center

Boston, USA: Global Innovation & Business Center

Singapore: Science Park Regional Business Center

2018

Born on the campus of Harvard University in May
August | MobiDrop Biotech (Shanghai) Co., Ltd. was officially founded
September | Secured angel round financing

2019

March | The world's first MobiChip digital PCR integrated microfluidic chip route passed the test
October | MobiDrop single-cell sequencing method passed the test

2020

01月与上海市第九人民医院及上海清华国际创新中心签署联合研发合作协议
05月与浙江省疾控中心签署研究合作框架协
08月与乌镇镇政府签署战略合作协议，墨卓生物科技(浙江)有限公司成立
10月获得Pre-A轮数千万元投资
11月微流体生物检测芯片项目获得2020年度桐乡精英引领人才等级A类
12月自主研发的第一代数字PCR一体机发布

2021

01月与单细胞测序服务头部企业签署战略合作协议
02月与同济大学共建单细胞测序联合研发中
04月获得第一张医疗器械备案
05月浙江乌镇生产基地正式启用

2022

04月 MobiNova®-100高通量单细胞测序建库系统上市
06月发表《Science》微生物单细胞基因组测序论文MobiMicrobe 微生物单细胞测序平台上市
07月完成近亿元A+轮融资
09月上海、嘉兴等多地研发中心启用
08-10月与多家知名科研服务商签订战略合作协议用
12月由长城战略咨询评选，墨卓生物入选“体外诊断”赛道中国新晋潜在独角兽企业
MobiCube®高通量单细胞V(D)试剂盒上市

2023

MobiNova®‑M1 微生物单细胞测序平台上市
被认定为浙江省企业研究院
受邀编写《2023 基因行业蓝皮书》
新加坡商务中心正式启用
完成 Pre‑B 轮融资

2024

首台 MobiNova®‑S1 单细胞分选仪顺利交付
单细胞微生物 Microbe‑seq 技术首篇应用文章发表
单细胞微生物 Microbe‑seq 技术入选 “十四五” 研究所教材《单细胞基因组学》
全球试剂盒销量突破 10000 份里程碑
正式启动出海战略，全年完成数十项海外业务签约，并亮相多个国际展会

2025

获评国家级专精特新 “小巨人” 企业
入选浙江省科技型 “新小龙” 企业
首篇 ChIP‑seq 技术应用文章发表《Nature Cell Biology》
全年发表高水平论文 65 篇，较 2024 年同比提升 4.5 倍
成功举办 2025 世界年互联网大会专题论坛、第三届微流控技术应用与创新高峰论坛
设备出海计划持续推进，业务覆盖日本、英国、匈牙利等国家
荣获首届全国 “数知通杯” 数据知识产权大赛二等奖

David A. Weitz Chief Scientific Advisor

Professor of Physics at Harvard University, Member of US National Academy of Sciences, Engineering and Arts & Sciences
500+ publications (30+ CNS papers)
Foreign Member of Chinese Academy of Engineering
89,000+ citations (h-index > 162)
Pioneer in microfluidics medical-engineering integration
Co-founded 12 high-tech companies